RT @BrJHaem: Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care & outcomes in a…

@Eddie_Cliff @SilasDay11 @mike_dickinson1 @ALLGtrials @Haem_pmcc_rmh Yes, one of those K-M quirks. The patients who died had progressed prior. The effect of the event on the PFS curve at an earlier time point was small (lots of pts at risk) whereas the effect on the OS curve at a later time point was larger (fewer pts at risk). Longer f/u needed!

RT @mike_dickinson1: #Glofitamab now US FDA approved for #DLBCL after 2 prior lines! Highly potent (CR43%),FIXED course, durable responses.…

RT @mike_dickinson1: #pembrolizumab is deliverable and effective as a monotherapy first treatment of #hodgkin #lymphoma in very frail patie…

RT @mike_dickinson1: We have TWO great clinical/research #fellowships in #lymphoma starting @Haem_pmcc_rmh in 2024 (one focussing on indole…

RT @thomaseliotlew: Just out in @TheLancetHaem! @AdrianMinson & I articulate the @Haem_pmcc_rmh approach to TP53-mutated MCL. From the li…

Congratulations to my mentor and colleague @mike_dickinson1 on the @NEJM publication of the pivotal phase II glofitamab data in DLBCL. So grateful to be involved in ongoing IITs using this highly active agent! @DocHutchings

RT @mike_dickinson1: Delighted that #glofitamab pivotal data for DLBCL is now online @NEJM. 39.4% CR in patients with the most common aggre…

@graham74GC Almost identical scenario discussed in our lymphoma multidisciplinary meeting this week at PMCC. Glad to see that we all struggle with this question!

RT @mike_dickinson1: Pleased to be presenting the bispecific #glofitamab pivotal data for R/R Large B cell #lymphoma #DLBCL at #ASCO22 This…

RT @mike_dickinson1: #POLARIX is Positive. RCHP-Pola versus RCHOP comes out in favour for the experimental arm. Well blow me down. Can’t wa…

RT @lymphomaOz: We welcome the announcement from @GregHuntMP & @GileadSciences that CAR T Cell Therapy Yescarta is now funded & available t…